Tuesday, September 8, 2009

Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101

Reuters reports that those who suffer from Psoriasis may soon have relief. Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today that its 75-patient Phase II clinical study with CF101 to treat patients with moderate to severe Psoriasis has successfully met its primary objectives.

Patients in this double-blind study were randomly assigned to 1, 2 or 4 mg of
CF101 or placebo twice daily. The drug was taken orally as a monotherapy for 12

Dr. Michael David, Head of the Department of Dermatology, Rabin Medical Center,
the study principal investigator said: "The study data is impressive and
promising. CF101 is a unique small molecule orally bioavailable drug with an
impressive safety profile based on accumulated experience in more than 700
patients. There is a market need in Psoriasis for small molecule drugs and I am
confident that Can Fite should progress with the clinical development of CF101
based on the study data."

For more information, please visit the original article.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment